Business
Easton Pharmaceuticals Provides Update On Acquiring Major Vaporizer and e-Liquids Manufacturer iBliss, Inc.
Easton Pharmaceuticals Provides Update On Acquiring Major Vaporizer and e-Liquids Manufacturer iBliss, Inc..
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Provides Update On Acquiring Major Vaporizer and e-Liquids Manufacturer iBliss, Inc.\n \n \nEaston Pharmaceuticals Provides Update On Acquiring Major Vaporizer and e-Liquids Manufacturer iBliss, Inc.\n\niBliss's Current Sales Are In the Millions Of Dollars and With An Anticipated Product Launch In New International Markets and Territories In Conjunction With Adequate Marketing Is Projected To Quickly Reach and Surpass $15,000,000 in Sales With Healthy Profit Margins in Excess of 40%\n\n \n TORONTO, ON--(Marketwired - Mar 8, 2017) - Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) provides an update on its acquisition of revenue producing vaporizer, e-liquids manufacturer and medical marijuana company, iBliss Inc., of Toronto, Ontario, Canada.\n Since the previously announced letter of intent to acquire revenue generating vaporizer manufacturer and medical marijuana company iBliss Inc., both parties have engaged in detailed negotiations to reach terms on a final closing agreement. Negotiations have now reached a stage where both companies are confident enough to expect an executed closing agreement within 1 week. Further information will be made available on a subsequent release when the transaction has been completed.\n Long Tran, CEO of iBliss, stated, \"Negotiations have unfortunately taken longer than expected, but recent consensus on outstanding issues has made a closing very realistic and is anticipated within a week following the passing of documentation between attorneys.\"\n iBliss is considered a fast growing vaporizer and e-liquids manufacturing company also involved in the medical marijuana industry, possessing surging international sales projected to realistically reach and surpass $15,000,000 per year once its products are launched in new international markets and territories in conjunction with an adequate marketing campaign through agreements executed with local distributors. iBliss currently generates several millions of dollars in sales with healthy margins in excess of 40%. iBliss has had tremendous growth over the past 3 years of being in business, which includes sales throughout North America and recently adding several international markets in Europe, the Middle East and Russia. iBliss possesses in house manufacturing of its own line of e-liquids products in a certified and ...